Andrew Jackson/LinkedIn
Aug 15, 2026, 16:58
Andrew Jackson: Oral Anticoagulants for the Prophylaxis of Catheter-Related Thrombosis
Andrew Jackson, Owner of IVTEAM LTD, shared a post on LinkedIn:
”Oral anticoagulants for the prophylaxis of catheter-related thrombosis
‘Prophylactic use of apixaban or rivaroxaban significantly reduces catheter-associated thrombosis and prolongs catheter survival compared with placebo, without an increased risk of bleeding’
Soliman et al (2026).”
Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments